TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 15/07/2024 BST 5-day change 1st Jan Change
144.4 USD +1.52% Intraday chart for TransMedics Group, Inc. -5.25% +82.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Adjusts TransMedics Group's PT to $170 From $120, Keeps Overweight Rating MT
Morgan Stanley Boosts Price Target on TransMedics Group to $145 From $104, Keeps Equalweight Rating MT
CL King Initiates TransMedics at Buy Rating With $161 Price Target MT
Transmedics Group Insider Sold Shares Worth $393,986, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $280,016, According to a Recent SEC Filing MT
Stephens Initiates TransMedics at Overweight Rating With $151 Price Target MT
Stephens Starts TransMedics Group With Overweight Rating, $151 Price Target MT
Transmedics Group Insider Sold Shares Worth $3,902,100, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $759,479, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $930,278, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $1,920,000, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $7,986,219, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $1,600,633, According to a Recent SEC Filing MT
TransMedics Group Shares Rise as Q1 Swings to Net Income, Revenue Rises; Increases 2024 Revenue Outlook MT
Oppenheimer Adjusts TransMedics Group Price Target to $125 From $105, Maintains Outperform Rating MT
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q1 Revenue $96.9M, vs. Street Est of $83.8M MT
TransMedics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Transcript : TransMedics Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024 CI
Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating MT
Top Premarket Gainers MT
Chart TransMedics Group, Inc.
More charts
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
144.4 USD
Average target price
146.4 USD
Spread / Average Target
+1.40%
Consensus
  1. Stock Market
  2. Equities
  3. TMDX Stock
  4. News TransMedics Group, Inc.
  5. Piper Sandler Adjusts TransMedics Group's PT to $170 From $120, Keeps Overweight Rating